Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
With FDA input pending, the companies are targeting a Phase 3 trial launch in the first half of 2026
BPC-157 upregulation of FGF contributes to: Fibroblast activation and collagen production Tissue remodeling during healing Blood vessel maturation FAK-Paxillin Pathway Activation The FAK (Focal Adhesion Kinase)-paxillin pathway is crucial for cell migration, adhesion, and survival
Expected timeline based on research: Initial vascular effects may begin within the first week
This research gap reflects the challenging regulatory landscape for peptides and the lack of pharmaceutical industry interest in compounds that cannot be patented
You and your doc will need to consider both options based on your unique situation
